Inhibikase (IKT) 10% Owner RA Capital Exchanges 18.03M Shares

What Happened
RA Capital Management, L.P. (through RA Capital Healthcare Fund, L.P.), a reported >10% owner of Inhibikase Therapeutics (IKT), exchanged 18,030,000 shares of IKT common stock on July 29, 2026 for a pre-funded warrant exercisable for up to 18,030,000 shares at an exercise price of $0.001 per share. The exchange was for no additional cash consideration. The filing reports both the disposition of the shares and the acquisition of the derivative (the pre-funded warrant).

Key Details

• Transaction date: July 29, 2026; Form 4 filed July 31, 2026 (appears to be within the 2-business-day reporting window).
• Shares disposed: 18,030,000 common shares (exchange).
• Derivative acquired: Pre-funded warrant exercisable for up to 18,030,000 shares at $0.001 per share; no expiration and exercisable immediately.
• Ownership cap: The warrant cannot be exercised to the extent that it would cause the Fund and its attribution parties to beneficially own more than 9.99% of outstanding common stock.
• Who holds the securities: The shares/warrant are held directly by RA Capital Healthcare Fund, L.P.; RA Capital Management, L.P. acts as the fund’s investment manager and disclaims beneficial ownership except to the extent of any pecuniary interest.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.

Context

• This is an institutional/investor re-structuring (a share-for-warrant exchange) rather than a typical insider purchase or sale by an executive; such transactions can be driven by fund-level tax, financing, or ownership-limit considerations and do not on their own signal executive sentiment.
• The pre-funded warrant is effectively a nearly immediate way to retain the economic interest in the underlying shares (exercise price nominal at $0.001) while being subject to a sub-10% ownership cap.